Epidemiology
Lipid pneumonia has been known to occur in underwater divers after breathing poorly filtered air supplied by a surface compressor lubricated by mineral oil. History
Laughlen first described lipid pneumonia in 1925 with infants that inhaled oil droplets. It is a condition that has been seen as an occupational risk for commercial diving operations but documented cases are rare. References
Further reading
Spickard, Anderson; Hirschmann, JV (28 March 1994). "Exogenous Lipoid Pneumonia". Archives of Internal Medicine. 154 (6): 686–92. doi:10.1001/archinte.1994.00420060122013. PMID 8129503. Betancourt, SL; Martinez-Jimenez, S; Rossi, SE; Truong, MT; Carrillo, J; Erasmus, JJ (January 2010). "Lipoid pneumonia: spectrum of clinical and radiologic manifestations". AJR. American Journal of Roentgenology. 194 (1): 103–9. doi:10.2214/ajr.09.3040. PMID 20028911. External links

Gross pathology specimen from the University of Utah
Previously, all triazole based drugs targeted fungal infections related to plants from Candida species. Since creation, terconazole has been superseded by second-generation triazoles due to their even broader spectrum and higher activity levels against resistant pathogens like Aspergillus spp. It is still used as a treatment in cases of resistance to other drugs. Available forms
Terconazole is a white, odourless powder. It can be purchased commercially in the following forms:

Terconazole 0.4% cream 5 g applied intravaginally once a day for 7 days;
Terconazole 0.8% cream 5 g applied intravaginally once a day for 3 days;
Terconazole 80 mg vaginal suppository used once daily for 3 days. References
External link
Information about terconazole from the United States Government